Research progress of roflumilast in the treatment of chronic obstructive pulmonary disease

Lin TONG,Hui-fang TANG

DOI: https://doi.org/10.13683/j.wph.2017.04.014

2017-01-01

Abstract:Chronic obstructive pulmonary disease (COPD) is a common disease characterized by persistent and progressive airflow limitation,which increases chronic inflammatory response in the airway with acute exacerbation and complications.Roflumilast is the only phosphodiesterase-4 inhibitor that can be oral administration for the treatment of COPD approved by the EU and FDA.Roflumilast has a strong anti-inflammatory effect and moderate bronchial dilatation,which can effectively improve lung function,and significantly reduce the deterioration in moderate and severe COPD patients,to prevent from acute exacerbations.This review summarizes the advances of roflurnilast in the clinical treatment of COPD.